← Leaderboards
Edmund K. Moon
University Of Pennsylvania
$2,330,962
Attributed
$2,330,962
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $368.3K · FY2012–20$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,330,962 · 2
By mechanism
R01$1,462,102 · 1
K08$868,860 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Steven Mark Albelda$22,046,338
- Daniel Sterman$5,215,085
- Melpo Christofidou-Solomidou$5,805,617
- Keith A Cengel$851,559
- Timothy C Zhu$9,831,408
Others in their field
Top investigators on “T-Cell Receptor”
- James C. Paulson · Scripps Research Institute$39,721,395
- Mark M Davis · Stanford University$34,705,255
- Paul Glyndwr Thomas · Boston Children'S Hospital$28,920,014
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$28,699,359
- David Wofsy · University Of California, San Francisco$25,028,600
- Bruce R. Blazar · University Of Minnesota$24,537,181
Research focus
T-Cell ReceptorCell PhysiologyMesotheliomaSignal TransductionNeoplastic CellTumor-Infiltrating LymphocytesExtracellularMalignant Pleural MesotheliomaResponseReceptorOutcome ForecastBaseT-LymphocyteTumorAdoptive TransferDoseImmunotherapyMalignant NeoplasmsAntibodiesChimeric Antigen ReceptorT Cell TherapyTumor MicroenvironmentNatural ImmunosuppressionChest
Grant awards (9)
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells$368,288
R01 · FY2020 · CA · contact PI
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells$357,238
R01 · FY2019 · CA · contact PI
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells$368,288
R01 · FY2018 · CA · contact PI
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells$368,288
R01 · FY2017 · CA · contact PI
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer$173,772
K08 · FY2016 · CA · contact PI
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer$173,772
K08 · FY2015 · CA · contact PI
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer$173,772
K08 · FY2014 · CA · contact PI
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer$173,772
K08 · FY2013 · CA · contact PI
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer$173,772
K08 · FY2012 · CA · contact PI